Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
Les Nouvelles - Licensing Executives Society International (LESI)
May 20, 2025 at 13:00 JST, Tokyo Japan
Jiayi Li, Ph.D., is a Technical Advisor in the firm’s Chemical Patent Prosecution group where she focuses on drafting patent applications for both domestics and international clients. With a strong background in organic and medicinal chemistry, Dr. Li leverages her extensive graduate/post-graduate research and regulatory experience to offer expertise across a wide range of areas, including organic chemistry, medicinal chemistry, pharmaceutical sciences, and life sciences.
Dr. Li obtained her Ph.D. in Organic Chemistry from Wayne State University in Detroit, MI. Her doctoral research focused on the development of stereoselective glycosylation reactions using small organic molecules as catalysts. This work involved organic synthesis, computational modeling, and intermediate identification, leading to the discovery of new reaction mechanisms. Additionally, Dr. Li investigated synthetic carbohydrate memetics both in silico and in vitro targeting heparanase inhibition. After completing her Ph.D., she joined Massachusetts Institute of Technology as a postdoctoral researcher, where she focused on developing methods in photocatalysis.
Prior to joining the firm, Dr. Li was awarded an ORISE fellowship in the Center of Drug Evaluation at the U.S. Food and Drug Administration. Her work involved development of validated analytical methods to assess the identity, composition, content, and higher order or microstructure of complex drugs employing a range of techniques, including nuclear magnetic resonance (NMR), dynamic light scattering (DLS), and fast protein liquid chromatography (FPLC).